Background. The safety and immunogenicity of the MRK adenovirus type 5 human immunodeficiency virus type 1 clade B gag/pol/nef vaccine, a replication-incompetent adenovirus type 5-vectored vaccine designed to elicit cell-mediated immunity against conserved human immunodeficiency virus proteins, was assessed in a phase 1 trial.
. Randomization of study participants. *Primary immunogenicity analysis performed at week 30 (4 weeks after the third injection).
mains unknown [13, [19] [20] [21] [22] [23] [24] . Virus-specific CD8 + cytotoxic T lymphocytes and CD4 + helper T lymphocytes appear to be critical for control of simian immunodeficiency virus and HIV infections [24] [25] [26] . Vaccines eliciting cell-mediated immunity to conserved HIV peptides may be effective in both the prevention and control of natural infection [20, 22, 23, 25, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . Vaccination with attenuated adenovirus type 5 (Ad5) vectors expressing HIV-1 gag has variably elicited strong cytotoxic T lymphocyte responses in primate models [45] [46] [47] [48] [49] [50] . Broad cellmediated immunity responses against multiple viral determinants may be more efficacious in preventing or slowing HIV infection [12, 14, 28, 51] .
We conducted a dose-ranging study of an HIV-1 vaccine, using a replication-incompetent MRKAd5 vector encoding HIV-1 gag, pol, and nef genes on the basis of near-consensus clade B sequences. Because immunity to Ad5 varies among populations and could affect vaccine responses [52] , safety and immunogenicity were evaluated in participants with and without preexisting Ad5 immunity. During preparation of this report, enrollment in a proof-of-concept trial with use of this vaccine to prevent or modulate HIV-1 infection was suspended because of lack of efficacy.
METHODS

Vaccine Composition
The MRKAd5 HIV-1 clade B gag/pol/nef vaccine consists of equal parts of 3 recombinant Ad5 vectors: MRKAd5gag [53] , MRKAd5pol, and MRKAd5nef. The E1 region of the Ad5 vector was deleted, which rendered the virus incapable of growing in human cells, and was replaced with a transgene construct that consisted of the human cytomegalovirus promoter [54] ; the HIV-1 clade B gag, pol, or nef open reading frame; and the bovine growth hormone poly A [55] . The open reading frames encode Gag from CAM-1, Pol (including only the reverse transcriptase and integrase gene products) from IIIB, and Nef from JRFL strains [56] . Gene sequences were codon optimized to enhance expression in mammalian cells [57] . The pol transgene segment was inactivated by substituting alanine codons for amino acids at enzymatically active sites [58] [59] [60] [61] [62] [63] [64] , and the nef transgene segment was inactivated through substitutions, which prevents attachment to the cytoplasmic membrane and retrotrafficking into endosomes [51] . The vaccine was formulated in 10 mmol TRIS buffer with 10 mmol histidine, 5% sucrose, 75 mmol sodium chloride, 1 mmol magnesium chloride, 0.1 mmol EDTA, 0.5% ethanol, and 0.02% polysorbate 80 (pH 7.4). Placebo consisted of an identical vehicle.
Objectives
The primary objectives of the study were to assess the safety, tolerability, and immunogenicity of a 3-dose regimen of the vaccine administered on day 1, at week 4, and at week 26 at doses of , ,
3 ϫ 10 3 ϫ 10 3 ϫ 10 3 ϫ 10 3 ϫ 10 total viral particles. Study participants were to be fol- 11 1 ϫ 10 lowed up for adverse events for 29 days after each dose. The primary immunogenicity end point was the proportion of study participants with a positive unfractionated Gag-, Pol-, or Nef- 
Study Design
This study was a multicenter, blind, randomized, dose-escalating, placebo-controlled trial of a homologous prime-boost 3-dose regimen in HIV-seronegative adults who would be followed up for up to 78 weeks for immunogenicity and 260 weeks for safety. Healthy HIV-seronegative study participants 18-50 years old were assessed for eligibility at 25 sites in the United States. Individuals were excluded if they were considered to be at high behavioral risk of acquiring HIV infection during the study on the basis of risk factor assessment. Individuals with chronic medical conditions, including chronic hepatitis B or C infection, were also excluded. The protocol was approved by review boards at participating centers. Written informed consent was obtained from participants. Ongoing risk assessments and preventive counseling were offered to participants during the trial. Enrolled study participants were randomized to receive 1.0-mL injections of placebo or vaccine into the deltoid muscle. Allocation schedules were computer generated. Investigators, study participants, clinical monitors, and laboratory personnel performing the biological assays were blind to treatment as- NOTE. Adverse events with combined incidence у5% for at least 1 of the active dose levels are displayed. Ad5, adenovirus type 5; dose units, viral particles per dose; n, no. of study participants with follow-up.
a Combined across baseline Ad5 strata with use of a weighted average that was based on observed stratum sizes in the trial (60.2% had Ad5 titers р200;
39.8% had Ad5 titers 1200).
b One-tailed for given dose versus placebo was based on a Cochran-Armitage trend test. Combined incidence is shown in bold if the P value remained P ! .025 !.025 after applying a multiplicity adjustment for the given dose level. Statistical comparisons were not performed within Ad5 strata because of small sample sizes.
signments. Study participants were initially enrolled in successive dose-escalating stages, allowing safety data from 6-8 participants at each dose level to be reviewed by an independent safety evaluation committee before participants were enrolled in the next higher dose group. Study participants were randomized to receive vaccine or placebo. Randomization with use of permuted blocks in the subsequent open-enrollment stage was stratified by baseline neutralizing anti-Ad5 antibody titers, to ensure adequate representation of study participants with low (р200) and high (1200) titers across groups.
For 5 days after each dose, study participants were to record the largest diameter of induration or erythema at the injection site. A vaccine report card was used to track daily temperatures and physical complaints for 29 days after each dose. Fever was defined as a temperature of у37.8ЊC. Surveillance for shedding MRKAd5 was to be performed during the 2-week postdose period by collecting pharyngeal samples for culture from study participants developing symptoms compatible with a viral respiratory tract infection and by collecting urine samples for culture from study participants experiencing symptoms of urinary tract infection or with asymptomatic hematuria or pyuria [65] .
Immunologic and Virologic Assays
Unfractionated IFN-g ELISPOT assays with 15mer HIV-1 peptide pools were performed to detect HIV-specific T cell responses [66, 67] . Clade B peptides homologous to the vaccine strain were used, except where specified. A positive ELISPOT response was defined as у55 spot-forming cells per 10 6 PBMCs 
NOTE.
A parallel modified intention-to-treat analysis including all participants who received у1 dose yielded similar results. ELISPOT, enzyme-linked immunosorbent spot; n, no. of study participants who were HIV seronegative through week 78, received all 3 doses, did not commit any major protocol violations, and had evaluable immunogenicity data at week 30.
a Combined across baseline adenovirus type 5 (Ad5) strata using a weighted average based on observed stratum sizes in the trial (60.2% had Ad5 titers р200;
39.8% had Ad5 titers 1200). b One-tailed for given dose versus placebo was based on a Cochran-Armitage trend test. P values for geometric mean ELISPOT responses were P ! .025 computed using an analogous trend test. ELISPOT responder is defined as у55 spot-forming cells per 10 6 PBMC and у4-fold increase over the nonantigen control; Pol responder is defined as responder to either Pol-1 or Pol-2 peptide pool. Overall, 173 (80%) of the 217 study participants included in the per-protocol immunogenicity analysis at week 30 had PBMCs processed under less than optimal conditions [66] . Statistical comparisons were not performed within Ad5 strata because of small sample sizes.
and a у4-fold increase over responses with use of the nonantigen control [67, 68] . Unless otherwise indicated, reported geometric mean ELISPOT responses include all study participants tested, regardless of whether their ELISPOT result was categorized as positive or negative. The T cell phenotype underlying the ELISPOT response was identified as CD4 and/or CD8 by intracellular cytokine staining [69] . Neutralizing antibody titers against Ad5 were measured using serial dilutions of serum obtained р45 days before the first injection and were measured periodically thereafter [70] .
HIV-1/2 EIAs (Abbott Laboratories) were to be performed at baseline, at week 78, and at the discretion of the investigator. Western blots were reflexively performed after positive EIA results. Plasma from study participants with indeterminate or positive immunoblots was tested for HIV by PCR (Amplicor 1.5; Roche Diagnostics).
Statistical Analyses
Safety. All study participants receiving у1 dose were included in the safety assessment. The proportions of study participants with adverse events р29 days after each dose were summarized by treatment group for each baseline anti-Ad5 antibody stratum. For the combined strata, summary statistics were calculated using a weighted average of the observed stratum-specific percentages, with weights proportional to the overall stratum sizes. Frequencies of specific adverse events in the vaccine and placebo groups were compared by the Cochran-Armitage trend test, starting with all the vaccine groups and sequentially excluding the highest remaining vaccine dose group as long as the difference versus placebo yielded a 1-tailed P value !.025.
To gauge which adverse events were likely to represent true signals rather than type 1 errors, P values were deemed to be statistically significant only if they remained !.025 after a multiplicity adjustment [71] . Immunogenicity. A per-protocol rather than intention-totreat approach was prespecified as the primary analysis, so that immune responses could be assessed under idealized conditions. Study participants without major protocol violations were included in the immunogenicity analyses. The proportion of ELISPOT responders was summarized by treatment arm at each time point [72] . Study week 30 was prespecified as the primary time point, because it was 4 weeks after the last vaccination. Differences in the frequencies of week 30 ELISPOT responders between a given vaccine dose group and the placebo group were analyzed using the Cochran-Armitage trend test. A 1-tailed P value !.025 was considered to be statistically significant; a multiplicity adjustment was not required, because a given dose was formally compared with placebo only if results of the trend tests for each higher dose were statistically significant [73] .
RESULTS
From 1 May 2003 through 29 June 2004
, 446 study participants were screened for eligibility (figure 1). Of 259 randomized study participants, 257 received у1 dose of vaccine or placebo. Two study participants randomized to vaccine groups did not receive any doses. All treated study participants were included in the safety analysis. The 212 vaccinated study participants randomized in the open-enrollment stage were stratified by baseline anti-Ad5 titers at entry. The placebo and vaccine groups were generally comparable in age, ethnicity, and baseline anti-Ad5 titer, although the placebo group had a higher proportion of women (table 1) . Overall, 40% of study participants had baseline anti-Ad5 titers 1200.
Before week 30, 12 vaccine recipients and 1 placebo recipient discontinued participation in the study because of loss to follow-up (12 study participants) or an adverse clinical event (fatal head trauma in 1 vaccine recipient). No individuals discontin- 6 PBMCs and a у4-fold increase over the nonantigen control. The data for the "Overall" entry were combined across baseline adenovirus type 5 (Ad5) strata with use of a weighted average that was based on observed stratum sizes in the trial (60.2% with anti-Ad5 titers р200; 39.8% with anti-Ad5 titers 1200). N, number of study participants with evaluable immunogenicity data; vp/d, viral particles per dose.
ued participation because of vaccine-related adverse events. Of 259 randomized subjects, ELISPOT results were available for 244 study participants (94%) at some point after randomization, including 217 study participants (84%) with data at the primary week 30 immunogenicity time point. A total of 229 study participants (88%) completed 78 weeks of the study and entered the long-term safety follow-up phase.
Six vaccine recipients received a diagnosis of HIV infection during the study (table 2) . Four of these study participants were excluded from the immunogenicity analysis, but the 2 subjects who received a diagnosis of HIV infection after week 78 were included in the analysis. In retrospect, all 6 study participants reported high-risk behavior during the study period.
Safety and Tolerability
No vaccine-related serious adverse events occurred in any group (95% CI, 0%-1.6%). The frequencies of injection-site reactions and systemic adverse events in the , , and 6 7 3 ϫ 10 3 ϫ 10 viral particles vaccine groups were similar to the cor- 8 3 ϫ 10 responding rates in the placebo group. Injection-site reactions that consisted primarily of local pain, erythema, and swelling occurred more frequently in vaccine recipients of the 2 highest doses than in placebo recipients (table 3) . Most study participants who received doses of viral particles and 10 3 ϫ 10 viral particles experienced injection-site discomfort. 11 1 ϫ 10 Fever, headache, and fatigue occurred more commonly among recipients of the higher vaccine doses than among those who received the placebo, especially in the viral particles 11 1 ϫ 10 dose group. Fever and nausea were more common among recipients of the and viral particles doses than 10 11 3 ϫ 10 1 ϫ 10 among those who received the placebo. Most documented temperatures in these dose groups (in 35 of 38 subjects [92%]) were !38.9ЊC. The proportions of study participants with local reactions remained fairly constant after each injection, whereas the incidence of systemic adverse events generally decreased with subsequent doses. Preexisting Ad5 immunity did not appear to affect the frequency of injection-site reactions. Participants with low baseline anti-Ad5 titers had numerically higher rates of systemic adverse events than did participants with high baseline anti-Ad5 titers.
Abnormal laboratory results in vaccine recipients at all doses developed at similar rates as in placebo recipients. From 305 adenoviral culture specimens obtained from 155 study participants, 1 urine specimen from a vaccine recipient in the viral particles dose group yielded Ad5; DNA was in- 9 3 ϫ 10 sufficient to determine whether the isolate was a vaccine strain. Four pregnancies were reported among vaccine recipients during the first 78 weeks of the study. Two resulted in the delivery of healthy full-term newborns at study weeks 104 and 118, 1 resulted in an elective abortion at 8 weeks of gestation at study week 33, and 1 resulted in a spontaneous abortion at 10 weeks of gestation at study week 32.
Immunogenicity
Vaccine induced ELISPOT responses against proteins encoded by all 3 transgenes in a dose-dependent fashion (table 4). In the highest 3 dose groups at the primary immunogenicity time point, the frequencies of positive ELISPOT responders and the ELISPOT geometric mean spot-forming cells per 10 6 PBMCs combined across baseline anti-Ad5 strata were significantly higher than in the placebo group for each peptide pool. In the viral particles dose group, 23 (72%) of 32 subjects had ELISPOT immune responses were attenuated in study participants with high versus low baseline anti-Ad5 antibody titers (figure 2). The effect of preexisting Ad5 immunity appeared to be partially overcome with higher vaccine doses (figure 3). Statistically significant ( ) inverse associations were found P ! .05 between Gag-ELISPOT responses and baseline Ad5 titers in the and dose groups ( ) but not in the 
DISCUSSION
In this phase 1 trial, the MRKAd5 trivalent vaccine was generally well tolerated. The frequencies of adverse events were dose related. The vaccine was immunogenic in healthy HIV-seronegative adults. In general, higher doses of vaccine induced immune responses to multiple HIV-1 peptides. Response rates to Gag proteins elicited by the trivalent vaccine were similar to historical results with the monovalent Ad5 vaccine, indicating that addition of pol and nef transgene vectors did not interfere with response to the gag vector [46] . The proportion of study participants with ELISPOT responses to the gag transgene 4 weeks after the third injection was greater than placebo at doses as low as viral particles, but consistent re- 6 3 ϫ 10 sponses to the pol and nef transgenes were not observed with low-dose vaccine. Quantitative ELISPOT responses elicited by all vaccine doses were stable from week 30 to at least week 78.
Positive ELISPOT responses in vaccine recipients with high preimmunization Ad5 titers were more common with higher doses. At the viral particles dose, ELISPOT responses 10 3 ϫ 10 were nearly equivalent in the low and high baseline anti-Ad5 strata. High preexisting Ad5 immunity did not dampen responses to the viral particles dose to the same degree 10 3 ϫ 10 as to the higher viral particles dose, possibly reflecting 11 1 ϫ 10 biological or assay variability versus a ceiling on the optimum dose of Ad5 vector. Because baseline and postvaccination Ad5 titers were comparable in study participants receiving the and viral particles doses, it is unlikely that 10 11 3 ϫ 10 1 ϫ 10 antibodies to the MRKAd5 vector boosted by the viral 11 1 ϫ 10 particles dose accounted for the difference in immunogenicity between the and viral particles dose groups 10 11 3 ϫ 10 1 ϫ 10 with high preexisting Ad5 immunity.
Positive EIA results were common in vaccine recipients. Vaccine dose and baseline Ad5 immunity were major determinants of vaccine-induced EIA positivity. In EIA-positive uninfected study participants, Western blots were typically indeterminate, with a characteristic band pattern directed at gag-encoded proteins. Although enrollment was restricted to adults with presumably low-risk behavior, 6 vaccine recipients received a diagnosis of HIV-1 infection during the study to date, under-scoring the difficulty of identifying a low-risk population for vaccine trials. Although no cases of HIV infection were recognized in placebo recipients, the composite vaccine group was ∼10 times larger than the placebo group. Of the 6 vaccine recipients infected during the time of the study, 3 study participants (50%) had high preexisting anti-Ad5 titers, 2 study participants (33%) received a full series of high-dose vaccine, and 5 study participants (83%) had negative or weakly positive ELISPOT responses. The predictive value of ELISPOT reactivity for clinical efficacy has not been established.
The trivalent vaccine induced broad cell-mediated immunity against HIV-1 clade B consensus peptides, with a predominant CD8-cell phenotype. Additional data are necessary to confirm whether this vaccine consistently elicits cell-mediated immunity to non-clade B peptides in different populations [74] [75] [76] [77] . On the basis of its balance of tolerability and immunogenicity, the viral particles dose was carried forward into phase 2 10 3 ϫ 10 trials evaluating whether the trivalent vaccine would be effective in the prevention and/or control of HIV-1 infection.
Despite the favorable immunogenicity of the vaccine candidate, enrollment in the proof-of-concept STEP trial that used this exact vaccine was recently stopped after a preplanned interim review by the Data and Safety Monitoring Board, because a futility analysis indicated that the study was unlikely to yield evidence of efficacy [78] . The STEP study was being conducted in areas of the world where HIV-1 infection caused by clade B predominates. The vaccine reduced neither the incidence of HIV acquisition nor the viral load set point in those who became infected. The disappointing results of the phase 2 trial, juxtaposed with our promising phase 1 data, highlight the challenges of developing an effective HIV-1 vaccine that targets cell-mediated immunity, especially the lack of reliable correlation between primate models versus human study participants and the unsolved challenge of identifying immune correlates of protection against HIV infection [48] [49] [50] [79] [80] [81] [82] . The discordance between the observed immunologic responses in our study and the preliminary efficacy findings from STEP indicate that the specific T cell responses elicited by vaccination were inadequate to prevent or modulate infection. Vaccine-induced activation of Ad5-primed T cells could theoretically increase susceptibility to HIV infection [81] . Strategies building on Ad5-vectored HIV-1 vaccines, such as heterologous prime-boost regimens or combination vaccines eliciting both cell-meditated and neutralizing humoral responses, may yet prove rewarding as the field of HIV vaccinology moves forward [83] . We hope that the ongoing analyses of the STEP results will provide instructive answers to many critical questions [84] . Financial support. Merck sponsored and funded this study. This work was also supported in part by the Center for AIDS Research (P30 AI27742 from the National Institute on Allergy and Infectious Diseases, National Institutes of Health, to the New York University School of Medicine). Manuscript preparation. The study was designed, managed, and analyzed by Merck Research Laboratories, in conjunction with external investigators. All authors had access to study data on request. This report was principally drafted by F.H.P., E.Q., R.M., D.V.M., and M.J.D. and was critically reviewed and ultimately approved by each coauthor in its essentially final form. The sponsor also reviewed the penultimate draft of the manuscript.
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